Vitamin K1 vs K2: Comparing MK-4 and MK-7 for Half-Life and Bone Support

Vitamin K1 and K2 are both forms of the same fat-soluble vitamin, but they behave differently in the body and show up in different foods. Understanding those differences can help you have a more informed conversation with your clinician about whether a supplement makes sense for you.

What Is Vitamin K and Why Does It Matter

Vitamin K is a fat-soluble vitamin that acts as a coenzyme for vitamin K-dependent carboxylase, the enzyme required to synthesize several proteins involved in hemostasis and bone metabolism. According to the NIH Office of Dietary Supplements (ODS), its two best-documented physiological roles are supporting the synthesis of prothrombin (clotting factor II), a plasma protein directly involved in blood clotting, and supporting the carboxylation of osteocalcin, a vitamin K-dependent protein in bone that may be involved in bone mineralization or turnover.

The NIH ODS also notes that gut bacteria produce menaquinones and that this bacterial production contributes to meeting the body's vitamin K requirement, though the exact contribution is not fully quantified (evidence grade: moderate).

The Three Forms You Will See on Labels

Vitamin K1 (Phylloquinone)

Phylloquinone is the predominant form in the diet, found mainly in green leafy vegetables such as kale, spinach, and broccoli. It is absorbed in the small intestine along with dietary fat, circulates primarily in the liver, and is cleared from the bloodstream relatively quickly. Because it is preferentially taken up by the liver, K1 is closely tied to the clotting-protein functions described above.

Vitamin K2 as MK-4 (Menaquinone-4)

MK-4 is a short-chain menaquinone found in animal-derived foods such as meat, eggs, and some dairy products. The body can also convert phylloquinone into MK-4 in certain tissues, including bone and arterial walls. MK-4 has a relatively short half-life, meaning blood levels rise and fall quickly after a dose, which is why research protocols using MK-4 have typically employed multiple doses per day to maintain tissue concentrations. Because MK-4 is distributed more broadly to extrahepatic tissues, it is studied more often in the context of bone and vascular proteins.

Vitamin K2 as MK-7 (Menaquinone-7)

MK-7 is a long-chain menaquinone produced by bacterial fermentation and found in meaningful amounts in natto, a fermented soybean food common in Japan. Its longer side chain makes it more bioavailable per microgram compared to K1, and its half-life is considerably longer, allowing a single daily dose to maintain more stable blood levels over a 24-hour period. This pharmacokinetic advantage has made MK-7 a popular choice in supplement research, particularly for studies looking at osteocalcin carboxylation.

Half-Life: Why It Matters Practically

Half-life describes how long it takes for the concentration of a substance in the blood to fall by half. K1 and MK-4 have short half-lives measured in hours, while MK-7 has a half-life measured in days. In practical terms, this means a single daily dose of MK-7 is more likely to maintain consistent circulating levels than the same dosing schedule with MK-4 or K1. Whether that translates into meaningfully better clinical outcomes for most people remains an active area of research, and no regulatory body has established a preferred form for supplementation.

Adequate Intake and Dietary Reference Values

The NIH ODS reports that the Adequate Intake (AI) for vitamin K is 120 micrograms per day for adult men and 90 micrograms per day for adult women. Importantly, no Recommended Dietary Allowance (RDA) has been established because the available data were not sufficient to set one. There is also no Tolerable Upper Intake Level (UL), reflecting that vitamin K has a low potential for toxicity at intakes found in foods and typical supplements.

These are population reference values. For personal dosing guidance, please consult a clinician or registered dietitian who can review your individual health history and medications.

What the Evidence Says About Bone Health

The NIH ODS rates the evidence that vitamin K supports carboxylation of osteocalcin and is involved in bone metabolism as strong. Osteocalcin must be carboxylated (a process requiring vitamin K) to function properly in bone tissue. However, the evidence that vitamin K supplementation reduces the risk of osteoporosis or bone fracture is rated as limited. This distinction is important: a well-established physiological role does not automatically mean that taking extra vitamin K in supplement form will produce a measurable clinical benefit in people who are not deficient.

Some studies have used high-dose MK-4 or MK-7 and observed improvements in markers such as carboxylated osteocalcin, but the translation of those biomarker changes into reduced fracture rates in the general population has not been consistently demonstrated. Readers should treat bone-health claims on supplement labels with appropriate caution.

Separately, the NIH ODS notes that higher menaquinone (K2) intake has been associated with less vascular calcification and lower coronary heart disease risk, but this evidence is also rated as limited and is not sufficient to support a clinical recommendation at this time.

Safety and Drug Interactions

Vitamin K has a low potential for toxicity and no upper limit has been set. However, the most important safety consideration is its interaction with anticoagulant medications. Warfarin (Coumadin) and similar vitamin K antagonists, including phenprocoumon, acenocoumarol, and tioclomarol, work by antagonizing vitamin K activity. Sudden changes in vitamin K intake from food or supplements can increase or decrease the anticoagulant effect, which can be serious and potentially dangerous. People taking these medications must keep their vitamin K intake consistent and should talk to a doctor or pharmacist before making any changes.

Additional interactions to be aware of, as noted by the NIH ODS, include the following.

• Antibiotics can destroy vitamin K-producing gut bacteria and may decrease vitamin K status. Cephalosporins such as cefoperazone may also inhibit vitamin K action directly.
• Bile acid sequestrants such as cholestyramine and colestipol can reduce absorption of vitamin K and other fat-soluble vitamins with long-term use.
• Orlistat reduces dietary fat absorption and can lower absorption of fat-soluble vitamins including vitamin K. When combined with warfarin, it may significantly increase prothrombin time.

If you take any of these medications, talk to your doctor before adding a vitamin K supplement in any form.

A Note on Supplement Labeling

Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease, and these statements have not been evaluated by the FDA. When comparing K1, MK-4, and MK-7 products, look for third-party testing seals, clear disclosure of the specific form and dose, and avoid products making disease treatment claims.

Bottom Line

K1, MK-4, and MK-7 all fulfill the same core physiological roles but differ in their food sources, tissue distribution, and how long they remain active in the body. The evidence for vitamin K's role in clotting and bone protein function is strong, while evidence that supplementation reduces fracture risk is limited. MK-7's longer half-life is a genuine pharmacokinetic difference, but it does not by itself confirm superior clinical outcomes. Speak with a clinician or pharmacist before starting any vitamin K supplement, particularly if you take anticoagulants or any of the other medications listed above.